Proactive Investors - Run By Investors For Investors

AdAlta capitalises on $5-million raising to progress drug to treat fibrotic diseases

AdAlta Ltd (ASX:1AD) chief executive officer Sam Cobb updates Proactive Investors on the health-focused company's recent $5 million raising to progress the development of its key AD-214 drug for the treatment of idiopathic pulmonary fibrosis.
 
Cobb says recent animal trials will soon progress to human testing in Australia.
 
The company aims to start phase-one studies in January 2020.
 
View full 1AD profile View Profile

Adalta Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use